{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:31:57Z","timestamp":1770913917591,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T00:00:00Z","timestamp":1488412800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00277-017-2950-9","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T22:15:24Z","timestamp":1488492924000},"page":"779-786","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Biosimilar epoetin alfa increases haemoglobin levels and brings cognitive and socio-relational benefits to elderly transfusion-dependent multiple myeloma patients: results from a pilot study"],"prefix":"10.1007","volume":"96","author":[{"given":"Roberto","family":"Castelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Sciara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Lambertenghi Deliliers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Pantaleo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,2]]},"reference":[{"key":"2950_CR1","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","volume":"118","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Bringhen S, Ludwig H et al (2011) Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118:4519\u20134529. doi: 10.1182\/blood-2011-06-358812","journal-title":"Blood"},{"key":"2950_CR2","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/ajh.24402","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV (2016) Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 91:719\u2013734. doi: 10.1002\/ajh.24402","journal-title":"Am J Hematol"},{"key":"2950_CR3","doi-asserted-by":"publisher","first-page":"813","DOI":"10.4065\/77.8.813","volume":"77","author":"SV Rajkumar","year":"2002","unstructured":"Rajkumar SV, Gertz MA, Kyle RA et al (2002) Current therapy for multiple myeloma. Mayo Clin Proc 77:813\u2013822. doi: 10.4065\/77.8.813","journal-title":"Mayo Clin Proc"},{"key":"2950_CR4","first-page":"233","volume":"2","author":"H Ludwig","year":"2004","unstructured":"Ludwig H, Pohl G, Osterborg A (2004) Anemia in multiple myeloma. Clin Adv Hematol Oncol 2:233\u2013241","journal-title":"Clin Adv Hematol Oncol"},{"key":"2950_CR5","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1158\/1078-0432.CCR-07-4153","volume":"14","author":"S Sharma","year":"2008","unstructured":"Sharma S, Nemeth E, Chen YH et al (2008) Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 14:3262\u20133267. doi: 10.1158\/1078-0432.CCR-07-4153","journal-title":"Clin Cancer Res"},{"key":"2950_CR6","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.hoc.2007.08.006","volume":"21","author":"J Blad\u00e9","year":"2007","unstructured":"Blad\u00e9 J, Rosi\u00f1ol L (2007) Complications of multiple myeloma. Hematol Oncol Clin North Am 21:1231\u20131246. doi: 10.1016\/j.hoc.2007.08.006","journal-title":"Hematol Oncol Clin North Am"},{"key":"2950_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1586\/14737140.2014.863153","volume":"14","author":"R Castelli","year":"2014","unstructured":"Castelli R, Orofino N, Losurdo A et al (2014) Choosing treatment options for patients with relapsed\/refractory multiple myeloma. Expert Rev Anticancer Ther 14:199\u2013215. doi: 10.1586\/14737140.2014.863153","journal-title":"Expert Rev Anticancer Ther"},{"key":"2950_CR8","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","volume":"351","author":"RA Kyle","year":"2004","unstructured":"Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860\u20131873. doi: 10.1056\/NEJMra041875","journal-title":"N Engl J Med"},{"key":"2950_CR9","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/1097-0142(20010815)92:4+<988::AID-CNCR1411>3.0.CO;2-O","volume":"92","author":"ML Winningham","year":"2001","unstructured":"Winningham ML (2001) Strategies for managing cancer-related fatigue syndrome: a rehabilitation approach. Cancer 92:988\u2013997","journal-title":"Cancer"},{"key":"2950_CR10","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdh235","volume":"15","author":"D Cella","year":"2004","unstructured":"Cella D, Kallich J, McDermott A, Xu X (2004) The longitudinal relationship of haemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 15:979\u2013986","journal-title":"Ann Oncol"},{"key":"2950_CR11","first-page":"13","volume":"34","author":"D Cella","year":"1997","unstructured":"Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34:13\u201319","journal-title":"Semin Hematol"},{"issue":"6","key":"2950_CR12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1017\/S0140525X13001180","volume":"36","author":"RA Wright","year":"2014","unstructured":"Wright RA, Pantaleo G (2014) Effort processes in achieving performance outcomes: interrelations among and roles of core constructs. Behav Brain Sci 36(6):705\u2013706. doi: 10.1017\/S0140525X13001180","journal-title":"Behav Brain Sci"},{"issue":"6","key":"2950_CR13","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s11031-014-9440-3","volume":"38","author":"G Pantaleo","year":"2014","unstructured":"Pantaleo G, Miron AM, Ferguson MA et al (2014) Effects of deterrence on intensity of group identification and efforts to protect group identity. Motiv and Emotion, Special Issue on Effort 38(6):855\u2013865. doi: 10.1007\/s11031-014-9440-3","journal-title":"Motiv and Emotion, Special Issue on Effort"},{"issue":"6","key":"2950_CR14","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00520-011-1220-y","volume":"20","author":"E Lamperti","year":"2012","unstructured":"Lamperti E, Pantaleo G, Finocchiaro CY et al (2012) Recurrent brain tumour: the impact of illness on patient\u2019s life. Support Care Cancer 20(6):1327\u20131332. doi: 10.1007\/s00520-011-1220-y","journal-title":"Support Care Cancer"},{"key":"2950_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.blre.2011.03.005","volume":"25","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Mateos M-V, Bringhen S, San Miguel JF (2011) Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? Blood Rev 25:181\u2013191. doi: 10.1016\/j.blre.2011.03.005","journal-title":"Blood Rev"},{"key":"2950_CR16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/bcp.13019","volume":"82","author":"A Douros","year":"2016","unstructured":"Douros A, Jobski K, Kollhorst B et al (2016) Risk of venous thromboembolism in cancer patients treated with epoetins or blood transfusions. Br J Clin Pharmacol 82:839\u2013848. doi: 10.1111\/bcp.13019","journal-title":"Br J Clin Pharmacol"},{"key":"2950_CR17","doi-asserted-by":"publisher","unstructured":"Palazzuoli A, Ruocco G, Pellegrini M et al (2014) The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions. Ther Clin Risk Manag 641. doi: 10.2147\/TCRM.S61551","DOI":"10.2147\/TCRM.S61551"},{"key":"2950_CR18","first-page":"380","volume":"72","author":"M Haag-Weber","year":"2009","unstructured":"Haag-Weber M, Vetter A, Thyroff-Friesinger U, INJ-Study Group (2009) Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol 72:380\u2013390","journal-title":"Clin Nephrol"},{"key":"2950_CR19","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s00277-014-2070-8","volume":"93","author":"R Castelli","year":"2014","unstructured":"Castelli R, Deliliers GL, Colombo R et al (2014) Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function. Ann Hematol 93:1523\u20131529. doi: 10.1007\/s00277-014-2070-8","journal-title":"Ann Hematol"},{"key":"2950_CR20","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2217\/fon.12.39","volume":"8","author":"L Kerkhofs","year":"2012","unstructured":"Kerkhofs L, Boschetti G, Lugini A et al (2012) Use of biosimilar epoetin to increase haemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience. Future Oncol 8:751\u2013756. doi: 10.2217\/fon.12.39","journal-title":"Future Oncol"},{"key":"2950_CR21","unstructured":"Rosti G, Petrini M, Bosi A et al. (2016) Managment of anaemia in onco-haematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study. Therapeutic Advances in Medical Oncology 2016"},{"key":"2950_CR22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) \u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189\u2013198","journal-title":"J Psychiatr Res"},{"key":"2950_CR23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.1365-2141.2001.02715.x","volume":"113","author":"F Dammacco","year":"2001","unstructured":"Dammacco F, Castoldi G, R\u00f6djer S (2001) Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113:172\u2013179","journal-title":"Br J Haematol"},{"key":"2950_CR24","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJM199006143222402","volume":"322","author":"H Ludwig","year":"1990","unstructured":"Ludwig H, Fritz E, Kotzmann H et al (1990) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693\u20131699. doi: 10.1056\/NEJM199006143222402","journal-title":"N Engl J Med"},{"key":"2950_CR25","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s12185-009-0378-2","volume":"90","author":"T Caravita","year":"2009","unstructured":"Caravita T, Siniscalchi A, Montanaro M et al (2009) High-dose epoetin alfa as induction treatment for severe anemia in multiple myeloma patients. Int J Hematol 90:270\u2013272. doi: 10.1007\/s12185-009-0378-2","journal-title":"Int J Hematol"},{"key":"2950_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/1758834012444499","volume":"4","author":"M Aapro","year":"2012","unstructured":"Aapro M, Cornes P, Sun D, Abraham I (2012) Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer. Ther Adv Med Oncol 4:95\u2013105. doi: 10.1177\/1758834012444499","journal-title":"Ther Adv Med Oncol"},{"key":"2950_CR27","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2217\/fon.14.43","volume":"10","author":"I Abraham","year":"2014","unstructured":"Abraham I, Han L, Sun D et al (2014) Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries. Future Oncol 10:1599\u20131609. doi: 10.2217\/fon.14.43","journal-title":"Future Oncol"},{"key":"2950_CR28","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P","volume":"91","author":"JJ Caro","year":"2001","unstructured":"Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91:2214\u20132221","journal-title":"Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-2950-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-2950-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-2950-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T11:47:43Z","timestamp":1498391263000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-2950-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,2]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["2950"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-2950-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,2]]}}}